medigraphic.com
ISSN 0016-3813 (Print)

2002, Number S1

<< Back

Gac Med Mex 2002; 138 (S1)

Selected Themes from the Hematology Laboratory

I. Certification and/or Accreditation. How To Get Them?
II. Transferrin-Soluble Receptor in Iron Deficiency.
III. Can a Group of Pediatric Patients with Low-Risk Acute Lymphoblastic Leukemia Be I

Romero-Guzmán LT, Pérez-Jáuregui J, Piedras J, Arana-Trejo RM

Language: Spanish
References: 33
Page: 165-173
PDF size: 65.06 Kb.


Text Extraction

No abstract


REFERENCES

  1. Guder WG, Narayanan S, Wisser H, Zawta B. Everything under control? En Samples: From the patient to the laboratory Second edition, Ed. GIT VERLAG 2001. p. 84-85.

  2. Brian S, Bull. Quality Assurance Strategies. En J. Koepke. Practical Laboratory Hematology. Churchill Livingstone Inc. 1991. p. 3-29.

  3. Marti GE, Steler-Stevenson, Bleesing JH, Fleisher TA. Introduction to flow cytometry. Seminars in Hematology 2001;38:93-99.

  4. Orfao A, Ruiz-Argüelles A, Lacombe F, Ault K, Basso G, Danova M. Flow cytometry: Its aplications to hematology. Haematologica 1995;80:69-81.

  5. Pui CH, Crist WM, Look T. Biology and clinical significance to cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990;76:1449-1463.

  6. Vindelov L, Christensen J, Jensen G, Nissen N. Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample – storage, staining and internal standardization. 1983; 3:332 -389.

  7. Look TA, Robertson P, Williams D. et al. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 1985;65:1079-1086.

  8. Kearney L, The impact of the new FISH technologies on the cytogenetics of haematological malignances. Br J Haemat 1999;104:648-658.

  9. Andrews NC. Disorders of iron metabolism. New Engl J Med 1999;341:1986-9.5

  10. Kailner A. Quality management in the medical laboratory: a comparison of draft standards. Clin Chim Acta 1998;278(2): 111-9

  11. NOM-166-SSA1-1997 México: Para la Organización y Funcionamiento de los Laboratorios Clínicos.

  12. Dybkaer R. Quality assurance, accreditation, and certification: needs and possibilities. Clin Chem 1994;40(7):1416-20.

  13. Lehmann HP Certification standards transfer: from committee to laboratory. Clin Chim Acta 1998;278(2):121-44.

  14. NMX-CC-004:1995 IMNC/ISO 9002 1994. México: Sistemas de calidad: modelo para el aseguramiento de la calidad en producción, instalación y servicio.

  15. Cook JD. The measurement of serum transferrin receptor. Am J Med Sci 1999;318:269-76.

  16. Kohgo Y, Nishisato T, Kondo K, et al. Circulating transferrin receptor in human serum. Br J Haematol 1986;64:277-81.

  17. Roault T, Rao K, Harford J, Mattia E Klausner RD. Hemin, chelatable iron, and the regulation of transferrin receptor biosynthesis. J Biol Chem 1985;260:14862-6.

  18. Simone JV, Verzoso MS, Rudy JA. Inicial features and prognosis in children with acute lymphocytic leukemia. Cancer 1975;36:2099-2108.

  19. Robbison L, Sather H, Coccia P et al. Assessment of the interrelationship of prognostic factors in childhood acute lymphoblastic leukemia. Am J Pediatr. Hematol Oncol 1980;2:3-5

  20. Romero F, Paredes R. Definición de riesgos en leucemia aguda, de acuerdo a la clasificación. In: Ruiz-Argüelles GJ, San-Miguel J, editors. Actualización en leucemias. 1st ed. Panamericana; 1996. p. 41-49

  21. Secker-Walker LM, Lawlev SD, Hardisty RM. Prognostic implication of chromosomal findings in acute lymphoblastic leukemia at diagnosis. Br Med J 1978;2:1529.

  22. Look T, Robertson PK, Williams DL, et al. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 1985;65:1079-1086.

  23. Secker-Walker LM, Chessells JM, Stewart EL, et al. Chromosomes and other prognostic factors in acute lymphoblastic leukemia. Br J Haematol 1989;72:336-342.

  24. Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiplid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85:751-756.

  25. Donadieu J, Auclevc MF, Baruchel A, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukemia:differences in outcome are poorly explained by the most significant prognostic variables. Br J Haematol 1998;102:729-739.

  26. Felix CA, Lange BJ, Chessells JM. Pediatric acute lymphoblastic leukemia: challenges and controversies in 2000. USA: Education Program Book. ASH; 2000. p. 285-302.

  27. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. Clinical uses and limitations of common molecular methodologies: from cloning to Southern, Northern, Western blotting and in situ techniques. In: Kurzrock R, Talpaz M, editors. Molecular Biology in Cancer Medicine. Martin Dunitz , 1995. p. 12-26.

  28. Lindual C, Norclenskould M, Porwit A, Bjorkholm M, Blennow E. Molecular cytogenetic characterization of acute myeloid leukemia and myelodisplastic syndromes with multiple chromosome rearrangements. Haematologica 2001;86:1158-1164.

  29. Kearney L. The impact of the new FISH technologies on the cytogenetics of haematological malignancies. Br J Haemat 1999;104:648-658.

  30. Kolomietz E, Brennan S, Karaskova J, Minkin S, Lipton J, Squire JA. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood, 2001; 97:3581-3588.

  31. Provan D, Gribben J. Molecular hematology. UK: Blackwell Science; 2000.

  32. Boultwood J, Fidler C. Molecular analysis of cancer. USA: Humana Press; 2002.

  33. Van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13:1901-1928.




2020     |     www.medigraphic.com